{
}
UBS has maintained a 'Neutral' rating on Roche, with analyst Matthew Weston highlighting that the focus of the upcoming annual results will likely be on the company's outlook for 2025. Roche operates in two main divisions: Pharmaceuticals and Diagnostics, developing treatments across various disease areas. The last closing price was 279.30 CHF, with an average target price of 302.71 CHF, indicating a potential upside of 8.38%.
UBS has maintained a 'Neutral' rating on Roche, with analyst Matthew Weston highlighting that the pharmaceutical company's upcoming annual results will be crucial for its 2025 outlook. The stock closed at $310.00, reflecting a 1.81% increase from the previous day.
Swiss bank UBS has upgraded Novartis to "Buy" with a price target of 111 francs ahead of the company's Q4 2024 results, due on January 31. Analyst Matthew Weston highlights concerns over the 2025 forecast, particularly the impending patent expiry for Entresto in the USA, which may hinder sales and earnings growth.
UBS has upgraded Novartis to a 'Buy' rating with a target price of 111 francs ahead of the final quarter 2024 figures, expected on January 31. Analyst Matthew Weston highlights investor caution due to the impending patent expiry for Entresto in the USA in mid-2025, which may impact sales and earnings growth.
UBS has maintained a 'Neutral' rating for Sartorius Stedim Biotech, setting a price target of 222 euros ahead of the upcoming fourth quarter results. Analyst Matthew Weston anticipates mixed outcomes, with ongoing recovery in the Bioprocess Consumables division, but expects management to lower medium-term targets significantly during the annual report.
UBS has maintained a 'Neutral' rating for Sartorius Stedim Biotech, setting a target price of 222 euros ahead of the upcoming fourth quarter results. Analyst Matthew Weston anticipates mixed outcomes, with ongoing recovery in the Bioprocess Consumables division, but expects management to lower medium-term targets significantly during the annual report.
UBS has maintained a 'Neutral' rating for Sartorius Stedim Biotech, setting a target price of 222 euros ahead of the upcoming fourth quarter results. Analyst Matthew Weston anticipates mixed outcomes, with ongoing recovery in the Bioprocess Consumables division, but expects management to lower medium-term targets significantly during the annual report. As of January 24, the stock was trading at 208.70 euros, reflecting a 0.53% increase.
UBS has maintained a "Neutral" rating for Sartorius with a target price of 280 euros ahead of the upcoming quarterly results. Analyst Matthew Weston anticipates a continued positive trend in customer orders within the Bioprocess Consumables segment for the fourth quarter.
UBS has maintained its "Buy" rating for Novartis, setting a target price of 111 francs. Analyst Matthew Weston highlighted the pharmaceutical company's new medium-term targets as a strong indicator of confidence, surpassing market consensus expectations.
UBS has maintained a "Buy" rating for Novartis shares, setting a target price of 111 francs, reflecting confidence in the company's new medium-term targets that exceed market expectations. On the day of the analysis, Novartis shares rose by 0.5% to CHF 91.48, indicating a potential upside of 21.34%. The stock has increased by 11.8% since the start of 2024, with Q4 2024 key figures expected on January 31, 2025.
Matthew Weston
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains neutral rating on roche ahead of annual results
22:37 27.01.2025
ubs maintains neutral rating on roche ahead of annual results
21:49 27.01.2025
ubs upgrades novartis to buy ahead of 2024 earnings report
15:36 27.01.2025
ubs upgrades novartis to buy with target price of 111 francs
14:36 27.01.2025
UBS maintains neutral rating for Sartorius Stedim with target at 222 euros
14:04 24.01.2025
ubs maintains neutral rating for sartorius stedim with target price of 222 euros
13:51 24.01.2025
ubs maintains neutral rating for sartorius stedim with target price of 222 euros
13:04 24.01.2025
UBS maintains neutral rating for Sartorius with target price of 280 euros
20:24 23.01.2025
UBS maintains buy rating for Novartis with target price of 111 francs
12:01 21.11.2024
ubs maintains buy rating for novartis with target price of 111 francs
10:01 21.11.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Retail and Consumer Goods
Global Financial Events
Finance Mergers & Acquisitions
Global Trade Developments
Industry Mergers & Acquisitions
Central Bank Actions
CEO Changes
Banking Regulations
Supply Chain Management
Startups & Entrepreneurship
Energy Sector Developments
Government Economic Policies
Workplace Trends
AI Innovations
Cryptocurrency Trends
Market Analysis and Predictions
Financial Scams and Security
Countries:
Companies:
The Goldman Sachs Group, Inc.
Bank of America Corporation
Apple Inc.
Alphabet Inc.
Barclays PLC
Tesla, Inc.
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank RV Global PP
Commerzbank AG
Lloyds Banking Group plc
PepsiCo, Inc.
BNP Paribas SA
Google Inc.
NVIDIA Corporation
UBS Group AG
Wix.com Ltd.
BP Castrol K.K.
Valvoline Inc.
Bosch Limited
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Indonesian Rupiah
Canadian Dollar
Russian Ruble
South Korean Won
United Arab Emirates Dirham
Offshore Chinese Yuan
Ghanaian Cedi
Hungarian Forint
Albanian Lek
Brazilian Real
Singapore Dollar
Qatari Riyal
Jordanian Dinar
People:
Donald Trump
Elon Musk
Warren Buffett
Sergey Brin
Larry Page
Goldman Sachs
Kelvin Taylor
Carsten Fritsch
Christopher Chandler
Scott Bessent
Martin Schlegel
Jerome Powell
Kubra Khan
Joe Biden
Volkmar Baur
Christopher Wallerstedt
Brian Moynihan
Airlangga Hartarto
Francesco Gaetano Caltagirone
Leonardo Del Vecchio